Use access key #2 to skip to page content.
$23.65 0.03 (0.13%)
8/29/2008 3:59 PM

Abraxis BioScience, Inc. (APPX)

CAPS Rating:
**

An integrated biopharmaceutical company which develops, manufactures and markets the portfolios of injectable products and leverage revolutionary technology.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating APPX

Add Stock to Watchlist

What the Community Thinks

Total Members

64 Outperforms
16 Underperforms
 

All-Stars

16 Outperforms
5 Underperforms
 

Wall Street

1 Outperforms
1 Underperforms
 

Members bullish on APPX are also bullish on:

Members bearish on APPX are also bearish on:

Ticker Tags

Drug Manufacturers - Major (27), Mid Cap (670)
Suggest a tag

Abraxis BioScience, Inc. At A Glance

Current Price: $23.65
Last Trade Time: 8/29/2008 3:59 PM
Open: $23.51
Previous Close: $23.62
Daily Range: $23.51 - $23.80
52-Week Range: $9.56 - $24.15
Volume: 86,701
Market Cap: $3.80B
P/E Ratio: 48.20
Compare Our Special Broker Offers!

Stock Trends

APPX VS S&P 500 (SPY)

APPX 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for APPX

More Headlines...

Top Bull Pitch

Recs

1

Abraxis BioScience, Inc. (APPX)

Avatar nickelndiamond (79.51) Submitted: 3/05/08 5:18 PM

Baxter produces approx. 50% of the heparin used in the U.S., with the FDA recalling their heparin and stopping production to investigate the increase in allergic reactions reported during January. The FDA has verified that APP will be able to provide 100% of the heparin need in the U.S. so that Baxt...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Abraxis BioScience, Inc. (APPX)

Avatar bioman100 (< 20) Submitted: 8/24/06 10:03 PM

CEO owns over 70% of stock, can't make market in this stock with big boys.

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 11 :   1 2 3 Next »

Recs

0

 (APPX)

Avatar SCOTTRHUETTLCPA (< 20) Submitted: 8/22/08 7:42 AM : Underperform Start Price: $23.46 APPX Score: -0.68

EPS > 70

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (APPX)

Avatar Robert685 (< 20) Submitted: 7/07/08 6:13 PM : Outperform Start Price: $23.06 APPX Score: -0.48

Get into BIO/Health Care -during the bear times

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (APPX)

Avatar Skates1616 (< 20) Submitted: 4/27/08 8:29 PM : Underperform Start Price: $13.05 APPX Score: -89.11

Too much debt for a long time to come...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (APPX)

Avatar nickelndiamond (79.51) Submitted: 3/05/08 5:18 PM : Outperform Start Price: $11.12 APPX Score: 115.83

Baxter produces approx. 50% of the heparin used in the U.S., with the FDA recalling their heparin and stopping production to investigate the increase in allergic reactions reported during January. The FDA has verified that APP will be able to provide 100% of the heparin need in the U.S. so that Baxter could voluntarily remove these products from use. This should not hurt Baxter much since they are such a large company with the heparin sales being just a fraction of their products they distribute but for APP a much smaller company this is an opportunity to expand and increase profits. I'm excited.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (APPX)

Avatar qasamm (94.86) Submitted: 2/13/08 6:26 PM : Outperform Start Price: $10.34 APPX Score: 134.68

Thrown into the news as the replacement option for Baxter's recalled Heprin APPX should see a nice jump in demand and profit. I think Baxter will be out of production for quite some time and loose their marketshare of this product which is less than 1% of their overall.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 11 :   1 2 3 Next »

Wall Street

Results 1 - 2 of 2  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackLazardCapit 87.26 02/23/07 Outperform NS $26.08-9.32%-11.26%+1.94
TrackJimCramer 81.79 08/17/06 Underperform 3W $24.09-1.83%-0.77%+1.06

Results 1 - 2 of 2  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners